

# BLOOD TRANSFUSION



## UK Blood Transfusion & Tissue Transplantation Guidelines

### Welcome

- This site presents the guidelines for the Blood Transfusion Services in the United Kingdom, covering the whole transfusion chain from donor selection to clinical use of blood components and donor selection, testing and processing of tissues. *By using this site you signify your acceptance of the conditions of use. [Click here](#) to read the "conditions of use" page.*




General  
Information



Guidelines for the Blood  
Transfusion Services  
in the UK



New Regulations  
Implementation



Document  
Library



Donor Selection  
Guidelines



Better Blood Transfusion

**DH** Department of Health **Toolkit**



JPAC Resources  
Members Area



Handbook of  
Transfusion Medicine



Systematic Review  
Initiative

# Updated Blood Product Transfusion policy & procedure on Intranet

University College London Hospitals **NHS**  
NHS Foundation Trust

## Blood Component Transfusion Policy & Procedure

May 2007  
Version 3.0



University College London Hospitals **NHS**  
NHS Foundation Trust

## Blood Component Transfusion Policy & Procedure

Policy ☒ Procedure ☐ Guideline ☐  
Trust Wide ☒ Local ☐

### Document Control Summary

Approved by & date	Clinical Guidelines Committee
Date of publication	May 2007
Review Date	May 2009
Creator & telephone details	<ul style="list-style-type: none"> <li>Dr. Jonathan Ward: Transfusion Consultant, ext. 9638, e-mail: <a href="mailto:j.ward@ucl.ac.uk">j.ward@ucl.ac.uk</a></li> <li>Jenny Berryman: BMS3 Transfusion, ext. 8522/3, e-mail: <a href="mailto:j.berryman@ucl.ac.uk">j.berryman@ucl.ac.uk</a></li> <li>Sasha Wilson: Blood Transfusion CNS, ext. 8096 bleep 7131 e-mail: <a href="mailto:sasha.wilson@ucl.ac.uk">sasha.wilson@ucl.ac.uk</a></li> </ul>
Distribution/availability	Trust Intranet Pages
Related documents/policies	<ul style="list-style-type: none"> <li>Control of Infection Manual</li> <li>Incidents, Serious Unwanted Incidents and Near Misses Policy</li> <li>Waste Management Policy</li> <li>Aseptic Non Touch Technique Guidelines</li> <li>Management of Massive Obstetric Haemorrhage Guidelines</li> </ul>
Implications of the Race Equality duties for this policy/strategy	This policy must be implemented fairly and without prejudice whether on the grounds of race, gender, sexual orientation or religion.

### Version Control Summary

Version	Date	Status	Comments/Changes
V3	May 2007	Approved	Clinical Guidelines Committee - May 2007 Minor changes only

UCL Hospitals is an NHS Foundation Trust incorporating the Eastman Dental Hospital, Elizabeth Garrett Anderson & Obstetric Hospital, The Heart Hospital, Hospital for Tropical Diseases, The Middlesex Hospital, National Hospital for Neurology & Neurosurgery, The Royal London Homeopathic Hospital and University College London Medical School.



# COMMUNICATION WITH BLOOD BANK

- ❖ Blood Bank is located on in The Doctors Laboratory in Whitfield Street.
- ❖ Routine service 09.00-17.00 Mon-Fri, 09.00-13.00 Sat (but fewer staff).
- ❖ Routine requests should not be made outside these hours.
- ❖ Sample reception.
- ❖ Major Haemorrhage/ Acute bleeding







# SAFE BLOOD TRANSFUSION TRAINING

## Why we need safe blood transfusion training?

- Legal Requirements
- Mandatory requirements
- Patient Safety

SERIOUS HAZARDS OF TRANSFUSION

**SHOT**





**Notice**  
9 November 2006

**Right patient, right blood**

Blood transfusions involve a complex sequence of activities and, to ensure the right patient receives the right blood, there must be strict checking procedures in place at each stage.

An initiative has been launched that offers a range of long and short term strategies to ensure blood transfusions are carried out safely. The National Patient Safety Agency (NPSA), the Chief Medical Officer's National Blood Transfusion Committee (NBTC) and Serious Hazards of Transfusion (SHOT) have collaborated to develop and evaluate these strategies.<sup>1</sup>

Administering the wrong blood type (ABO incompatibility) is the most serious outcome of error during transfusion. Most of these incidents are due to the failure of the final identity checks carried out between the patient (at the patient's side) and the blood to be transfused.

SHOT data have shown that between 1996 and 2006, five patients died as a direct result of being given ABO incompatible blood. ABO incompatibility contributed to the deaths of a further nine patients and caused major morbidity in 54 patients.<sup>2</sup>

**Action for the NHS and the independent sector**

By May 2007, all NHS and independent sector organisations responsible for administering blood transfusions in England and Wales should have:

1. Agreed to and started to implement an action plan for competency-based training and assessment for all staff involved in blood transfusions.
2. Ensured that the compatibility form (or equivalent) and patient notes are used as part of the final check at the patient's side. The bloods comply with their blood transfusion policy which stipulates that the final identity check must be done next to the patient by matching the blood pack with the patient's variables (or identity band/identity card).
2. Systematically examined their local blood transfusion procedures, using a formal risk assessment process, and approved the feasibility and relevance of using:
  - a. bar codes or other electronic identification and tracking systems for patients, samples and blood products (a clinical transfusion management system);
  - b. photo identification cards for patients who undergo regular blood transfusions;
  - c. a labelling system of matching samples and blood for transfusion to the patient (microarray).





# **The Cost of Blood Products**

## **2007/08**

- **Standard red cells £133.99**
- **Platelets £208.46**
- **Premium for HLA matched + £147.59**
- **Premium for CMV Neg + £6.86**
- **Standard FFP £32.69 (£130.76 4 bags)**
- **Pooled Cryoprecipitate £219.87**



# **SERIOUS HAZARDS OF TRANSFUSION REPORT & RISK MANAGEMENT**



In Safety information

- Safety warnings, alerts and recalls
- General safety information and advice
- How we monitor the safety of products
- Reporting safety problems
- > Medicines
- > Devices
- > Blood

Home > Safety information > Reporting safety problems

Reporting safety problems

This section provides access to information on how to report suspected safety problems with medicines, medical devices, blood and blood components.

Medicines

Report a suspected adverse reaction or defect

The MHRA collects information on suspected adverse drug reactions and suspected defects in medicinal products.



Devices

Report an adverse incident

Any adverse incident involving a medical device or its instructions for use should be reported to the MHRA, especially if it lead to, or could have lead to, death, life-threatening illness or injury.



Blood

Report an adverse event or reaction

From 8 November 2005 the EU Blood Safety Directive will require that serious adverse events and serious adverse reactions related to blood and blood components are reported to the MHRA, the UK Competent Authority for blood safety.







# **SERIOUS HAZARDS OF TRANSFUSION REPORT**

- **Serious Hazards of Transfusion (SHOT) is a UK confidential enquiry it was launched in 1996.**
- **Transfusion errors, near miss events and serious adverse incidents are reported to SHOT. The National data is analysed and an annual report is published.**
- **Now in it's 11<sup>th</sup> year the SHOT enquiry provides an increasingly authoritative analysis of serious transfusion complications in the UK.**
- **Incorrect blood component transfused remains the most frequent transfusion hazard in the 2003/04 report, as in all previous years.**



# SERIOUS HAZARDS OF TRANSFUSION REPORT

Numbers of incidents included in the analyses (n=3239)




Figure 5

The patient got the wrong blood

FILM

RESTAURANTS

PUBS & BARS

THEATRE & COMEDY

MUSIC

ARTS & EXHIBITIONS

EVENTS

CLUBBING

SHOWBIZ

NEWS

News in brief  
Real-time Tube map

SPORT

HAVE YOUR SAY

BLOGS

LOCAL LISTINGS

Add your own listing

CRITICS' CHOICE

MUSIC  
CHRIS ELWELL-SUTTON

"50 Cent wrapped his music up in an irresistibly appealing package"



50 Cent»

THEATRE & COMEDY

## GRAN DIES AFTER BEING GIVEN WRONG BLOOD TYPE

22.05.07

Q Add your view

A great-grandmother died after being given the wrong type of blood during a hospital transfusion.

Margaret Davies, 67, was given type A instead of type O when her case notes are believed to have been mixed up with those of another patient with the same name.

Scroll down for more



The Last Confession»

MUSIC

JOHN AIZLEWOOD

"Reed didn't merely replay Berlin, he re-imagined and re-created it"



Lou Reed»

READER REVIEWS

THEATRE & COMEDY

Victoria, London

"Shylock was played as a victim as much as the aggressor. I would recommend this production to anyone."

The Merchant Of Venice»

MUSIC

Lisa, London

"Great songs and great venue, but the guy has no personality!"

Snow Patrol»

PUBS & BARS

Alison, London

"One of my favourite pubs. Looking forward to going back to see what it's like now it's smoke-free"

The Grange»

She died the following day. Three nurses have been suspended and police have launched an investigation into the death at Whiston Hospital, Merseyside.

Her devastated husband, Malcolm, also 67, said he would be taking legal action.

"It was like giving her a lethal injection," he said.

"It is unbelievable. My wife was a beautiful woman who lived for her family. She deserved better than this."

Scroll down for more



# **SERIOUS HAZARDS OF TRANSFUSION**

## **REPORT: Wrong Blood examples.**

### ➡ **Case 1:**

- Patient, first on operating list, was second but order changed.
- Blood for original first patient collected from fridge but not checked thoroughly.
- Unit was transfused.

- When second unit was collected from fridge, the error was discovered.
- Patient was group O. Transfused with one unit group B.
- Patient died.





# **SERIOUS HAZARDS OF TRANSFUSION REPORT & RISK MANAGEMENT**

**SAFER  
PRACTISE  
TAKES  
MINUTES!**





# **RISK OF TRANSFUSION TRANSMITTED INFECTION IN UK**

- **The risk of catching hepatitis from a blood transfusion is very low – about 1 in 900,000 for hepatitis B (in fact, you are more likely to be struck by lightning).**
- **Less than 1 in 30 million for hepatitis C following the introduction of PCR testing.**
- **The chance of HIV infection is less than 1 in several million.**
- **As yet, we don't know the level of risk of new variant Creutzfeldt-Jakob Disease (vCJD) being transmitted by blood. However, a number of precautions have been introduced to minimise the risk.**

# Label Change to all UK Blood Components

The labels on all UK Blood Components will change to contain the following wording:

*Always check patient/component compatibility/identity*

*Inspect pack for signs of deterioration or damage*

*Risk of adverse reaction/infection, including vCJD*


See example label with advice circled in red shown below.

### Who requested this change?

The UK Forum i.e. the Medical Directors and Chief Executives from the 4 UK blood services. The Forum meets regularly to help ensure a common approach to all aspects of quality and safety relating to the blood supply.

### When will the labels change?

The implementation date is 1st July 2007



### Is anything being removed from the label?

The filter administration information is not a label requirement and will therefore be removed

### Will all labels change at the same time?

The change will be prospective not retrospective so, for example, we will not be re-labelling frozen components. Consequently you will see both the old and new label format for some time.

### Why is vCJD specifically mentioned?

This was in response to legal advice because the magnitude of risk for vCJD is unknown compared to other known infectious risks such as HIV or HCV.




# Blood Transfusion In Emergencies

- ✱ Unmatched emergency group O: In all satellite fridges except haematology.
- ✱ Unmatched group O blood should only be used when the patients life would be at risk if there were any delays in giving blood.
- ✱ Blood should always be carefully crossmatched except in extreme emergencies.
- ✱ **O Rh D negative** blood is often referred to as the 'Universal donor' in practise this term is dangerous and misleading. There are many patients with red cell antibodies that may cause transfusion problems.
- ✱ Unmatched **Group O Rh D positive** can be given to men > 40 or post menopausal women > 50






# E.U. Directive: Blood Safety & Quality Regulations 2005




**Traceability requirements:**

***Regulation 9 (1) (e) requires hospital blood banks to:***

***'maintain, for not less than 30 years, the data needed to ensure full traceability of blood and blood components, from the point of receipt of the blood or blood component by the hospital blood bank.'***



# Traceability



**Slip must be signed and returned  
– only after you have confirmed  
identity of recipient**

The image shows a pink medical slip with a white label. The label contains the following fields:

PATIENT:	UNIT NO.
HOSP. NO.	PRODUCT
GROUP:	UNIT GROUP
WARD:	EXPIRY DATE
DATE ISSUED:	TAKEN BY:
DATE REQD.	DATE TAKEN:
LAB ACC. NO.	TIME TAKEN:

A black circle highlights the 'TAKEN BY' and 'DATE TAKEN' fields.

● Blood location

● Requesting blood products - porters

● Blood Fridges

● Blood Register

● Blood Receipt

Form number:

### Blood Component Receipt Form

University College London Hospitals NHS Foundation Trust

Patent identification Details must be fully completed

Hospital Number: Surname: First Name: D.O.B.	The patient's full name, date of birth and hospital number must be clearly stated to portering controllers if requesting porters to collect blood components.  If blood is being collected by ward/department staff this form must be completed and taken to the blood fridge/platelet fridge and the patient's ID details checked against those on the component pack.
Ward/Clinical Area:	A complete audit trail for the transport & distribution of blood components is a legal requirement and must be maintained to ensure compliance with Blood Quality and Safety regulations.

Component requested (mark box with X)	Number of units/ volume requested
Red Blood Cells <input type="checkbox"/>	
Platelets <input type="checkbox"/>	
Red Frozen Plasma (FFP) <input type="checkbox"/>	
Cryoprecipitate <input type="checkbox"/>	
Other (Please State) <input type="checkbox"/>	

Requested by:			
Printname:		Signature:	
Date:	Time:	Job title:	

Patient Details on blood products ordered as correct and collected by:			
Printname:		Signature:	
Date:	Time:	Job title & Job no. (if porter):	

Patient Details on blood products ordered as correct and received by:			
Printname:		Signature:	
Date:	Time:	Job title:	

If there are any discrepancies when checking ID details inform Blood Bank



# BLOOD PRODUCT REGISTER



**THE MOVEMENT OF ALL BLOOD PRODUCTS INTO AND OUT OF THE BLOOD FRIDGE MUST BE RECORDED AT ALL TIMES.**

**A COMPLETE AUDIT TRAIL IS REQUIRED FOR COMPLIANCE WITH THE BLOOD QUALITY AND SAFETY REGULATIONS 2005**

**NEVER RETURN BLOOD TO THE FRIDGE WHICH HAS BEEN OUT FOR MORE THAN 30mins WITHOUT INFORMING THE LAB**



# BLOOD FRIDGES

- ▶ Blood that has been out of a blood fridge for more than 30 mins must never be put back in a blood fridge without labelling "not for transfusion" & informing Blood Bank.
- ▶ If the blood transfusion can't be completed within 4hrs after removal, the blood is not safe for transfusion and Blood Bank must be informed so the unit can be fated and destroyed.

- ▶ Remember to check all patients details!
- ▶ Platelets must never go in a fridge.





# Administration

- ✱ The final check for any blood product must be the patients wristband against details on pack; no wristband, no transfusion.
- ✱ Observations must be recorded, pre-transfusion, 15mins into, transfusion and post transfusion, even if on continuous monitoring.
- ✱ Red cell transfusion should not exceed 4 hours: Blood should remain in a blood fridge until ready to. check and transfuse.
- ✱ All blood products must be given through a set which has a 170-200 micron screen filter.
- ✱ Cryoprecipitate and FFP should be transfused rapidly: approx 10mls/min.

## CMV NEGATIVE COMPONENTS REQUIRED

Sig:

## IRRADIATED COMPONENTS REQUIRED

Sig:

## IRRAD/CMV NEGATIVE COMPONENTS REQUIRED

Sig:

# Does your patient need blood with special requirements?


Issued 01/06

- CMV negative blood components help minimise the risk of cytomegalovirus (CMV) transmission
- Irradiated blood components are needed to prevent development of transfusion-associated graft-versus-host disease (TA-GvHD)
- Antigen negative red cells are required to prevent haemolytic transfusion reactions in patients with red cell antibodies



Label before  
irradiation

To show the  
blood  
product has  
been  
irradiated,  
the 'NOT'  
part of the  
label will  
disappear



Additional  
blood group  
information  
is detailed  
here

If the blood  
product is  
CMV  
Negative it  
will be  
stated here





# ACUTE MASSIVE BLOOD LOSS

- Complications of major blood loss and massive transfusion may jeopardize the survival of patients from many specialities. Avoidable deaths of patients with major haemorrhage are well recognised.
- Massive blood loss is normally defined as the loss of one blood volume in 24 hrs (normal blood volume approx 7% IBW adults & 8-9% in children). An alternative definition is loss of 50% blood volume in 3hrs and/or  $>150\text{mls/min}$ . (Adult - approx EBV  $70\text{mls/kg}$ )



# ACUTE MASSIVE BLOOD LOSS

- **ANTICIPATE THE NEED FOR & ORDER COMPONENTS EARLY** additional platelets may need to be ordered from.
- Early and clear communication essential for optimal management – state ‘major haemorrhage’ when communicating with blood bank.





# ACUTE MASSIVE BLOOD LOSS

- Blood loss is usually underestimated, haemoglobin and haematocrit values to not fall for some while after acute haemorrhage.
- Red cell transfusion is likely to be required when 30-40% of blood volume is lost; the loss of  $>40\%$  blood volume is immediately life threatening.





# ACUTE MASSIVE BLOOD LOSS

- ▶ Blood clotting factors may be severely diminished by blood loss and red cell transfusion alone will not replace.
- ▶ Disseminated intravascular coagulation may (D.I.C.) may occur.
- ▶ Recombinant Factor VIIa may be a consideration.

- ▶ **REMEMBER  
DOCUMENTATION  
AND  
IDENTIFICATION**







# ACUTE MASSIVE BLOOD LOSS

## ● Red cells

- ▶ (In 70 Kg adult) : One unit of packed cells increases Hb by 1g/dl. 500ml loss represents 10% loss [approx. 1g fall in Hb], 2000mls represents 40% loss [approx. 4g-5g fall in Hb]
- ▶ a: Blood needed immediately: Group O RhD neg (Rh D pos may be suitable): Hb = <5g/dl (Emergency Stock). 40 -50% EBV Loss.
- ▶ b: Blood needed within 20 to 45 minutes. Uncrossmatched group specific. (Hb = <8g/dl and ongoing blood loss)
- ▶ c: Blood needed in 60 minutes: Full crossmatch.



# ACUTE MASSIVE BLOOD LOSS

## ● Platelets

- ▶ A platelet count of  $50 \times 10^9/L$  should be anticipated after approx 2 blood volumes have been replaced.
- ▶ Be prepared to request platelets in advance of need, if there is multiple trauma, head injury, abnormal platelet function (aspirin) or persistent active bleeding.
- ▶ Target values:  $50 \times 10^9/L$  *but*  $100 \times 10^9/L$  if multiple or CNS trauma or abnormal platelet function.
- ▶ Dosage: 1 -2 pooled packs of platelets for an adult.



# ACUTE MASSIVE BLOOD LOSS

## ● Fresh frozen Plasma (FFP):


- ▶ Anticipate coagulation factor deficiency after blood loss replacement  $> 1.5$  EBV loss.
- ▶ N.B.: Fluid resuscitation will further reduce coagulation factor levels because of dilution. FFP may be required early ( $>0.5$  EBV) if there is ongoing blood loss and fluid replacement. FFP : Indicated if  $PT/aPTT > 1.5 \times \text{control}$ . Dosage: 12 -15 mls/Kg body weight (4 packs for an adult).
- ▶ **Empirical treatment may be necessary** if evidence of generalised bleeding and coagulation tests are not available



# ACUTE MASSIVE BLOOD LOSS

## ● Cryoprecipitate:

- ▶ Fibrinogen deficiency may develop when  $> 1$  EBV replaced. Treat if Fibrinogen levels  $< 1.0\text{g/dl}$ .
- ▶ Dosage: 1 unit /5 Kg body weight (10 -15 units for an adult – **since November 2005 pooled product now 5 units per bag**)







# PRESCRIBING



- ✗ The decision to transfuse should be made on an individual patient basis.
- ✗ Transfusion of allogeneic blood **should not** be carried out just to achieve normal Hb.
- ✗ Essential where Hb is 5gm/dl or below
- ✗ Strongly indicated where Hb below 7 gm/dl
- ✗ Can be required below 8gm/dl
- ✗ Cause of anaemia should be investigated esp. prior to routine surgery. RCT should not be used where effective alternatives exist.
- ✗ A normal red cell transfusion can be given in 2-3 hrs.
- ✗ Platelets should given over not more than 30 mins.



# PRESCRIBING



## ➤ Platelets

- Dose: usually one pool
- **Patient actively bleeding**: indicated where
  - count  $< 50 \times 10^9/L$
  - platelet function defect
  - acute DIC
- **Patient NOT bleeding**: indicated when
  - $< 10 \times 10^9/L$  if temporary myelosuppression, ( $< 20 \times 10^9/L$  if fever or minor haemorrhagic signs)
  - $< 100 \times 10^9/L$  if surgery on critical areas (brain, eye)
  - $< 50 \times 10^9/L$  if patient is having lumbar puncture, transbronchial biopsy, insertion of indwelling catheter, liver biopsy etc
  - post cardiopulmonary bypass



# PRESCRIBING FFP



- ➡ **What is the patient's PT/APTT?**
- ✗ **Starting dose: 12-15ml/Kg body weight (approx. 4 bags in adult patient - often under prescribed)**
- ✗ **Indicated for:**
  - patients with DIC
  - patients with TTP (Octoplas now indicated first line)
  - Haemorrhage with coagulation abnormalities
  - Immediate reversal of Warfarin (pre-op) but **MUST** consider Vitamin K
  - Inherited deficiencies of coagulation (in absence of specific concentrates)
- ✗ **May be needed for:**
  - massive transfusion
  - bleeding or proposed surgery with Liver disease

- Patient Blood Transfusion Status forms must be sent to Blood Transfusion **BEFORE** blood products are requested.
- Email to **BT status** (attach a read receipt).
- If faxing ring the laboratory to confirm receipt.
- Print a copy of the form and the **current** copy must be kept in the patients folder.
- Review CMV status if unknown & amend status as soon as known if +ve

UCLH BLOOD TRANSFUSION DEPARTMENT: BLOOD PRODUCT STATUS FORM	
Email form to: BT Status – select from hospital Email address book (attach read receipt & if no computer access Fax to: 020 7 380- 9687 (phone lab to confirm receipt & if no computer access Fax to: 020 7 380- 9687 (phone lab to confirm receipt & if no computer access	
Hospital number	<input type="text"/>
Surname	<input type="text"/>
Forename	<input type="text"/>
Date of birth	<input type="text"/> <input type="text"/> <input type="text"/> Sex <input type="text"/>
Diagnosis	Treatment plan
IF HLA PLATELETS REQUIRED ARRANGED DIRECTLY WITH NATIONAL BLOOD SERVICE AND INFORM LABORATORY EXT.8623/8622	
Irradiated products required <i>(Place X in appropriate box)</i>	<input type="checkbox"/> Yes <input type="checkbox"/> No Start date: <input type="text"/>
Indications for irradiated blood products: <ul style="list-style-type: none"> <li>• PBSC/ BMT (Patients &amp; Donors): From 7 days pre harvest for solid organ transplant conditioning. Allogeneic - Discontinue at 6 months post transplant or when immunosuppression tapered. Autologous - Discontinue at 3 months post transplant, although 6 months recommended for TBI.</li> <li>• Hodgkin's disease: irradiate all stages regardless of treatment.</li> <li>• Treatment with purine analogues: Eg. Fludarabine, Deoxycothymidine (DCFT), 2-Chlorodeoxyadenosine (2-CDAA) or treatment with Campath.</li> <li>• Fetal Medicine: IU.T. and for 1 year post IU.T. / Exchange transfusion.</li> <li>• Congenital immune deficiency syndrome e.g. Ig A deficiency.</li> <li>• Patients with chronic GVHD, on immunosuppressive therapy.</li> <li>• HLA selected platelet/ Granulocyte or Buffy Coat transfusions</li> <li>• Transfusion from 1st or 2nd degree relative</li> </ul>	
CMV Negative products required <i>(Place X in appropriate box)</i>	<input type="checkbox"/> Yes <input type="checkbox"/> No Start date: <input type="text"/>
Indications for CMV negative blood products: <u>If CMV Status unknown update lab as soon as result known.</u> <ul style="list-style-type: none"> <li>• CMV negative PBSC/ BMT organ transplant recipients or potential recipients, <u>until status known.</u></li> <li>• Fetal Medicine - IU.T. / Exchange transfusion/ Neonatal transfusion.</li> <li>• H.I.V.</li> <li>• Pregnant women: <u>essential delivery.</u></li> <li>• Congenital immune deficiencies.</li> </ul>	
Washed products required <input type="checkbox"/> Yes <input type="checkbox"/> No	Start date: <input type="text"/>
Single Donor platelets required <i>(Children &lt; 16 or by arrangement with Transfusion SpR blood 7050)</i>	<input type="checkbox"/> Yes <input type="checkbox"/> No Start date: <input type="text"/>
<i>(Place X in appropriate box)</i>	
Requested by: Designation:	Signature or login code: Date of request:
ENSURE THAT STICKERS ARE ON DRUG CHART. STATUS FORM ONCE SENT <u>MUST</u> BE KEPT IN NURSING FOLDER.	